The Confirmatory Olmesartan Plaque Regression Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 114 participants.

Also called NCT01132768

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01132768
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01132768. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Confirmatory Olmesartan Plaque Regression Study
Acronym
CONFIRM
Condition
Essential Hypertension
Condition
Carotid Plaque
Intervention (Drug)
Atenolol
Intervention (Drug)
olmesartan medoxomil
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (class: industry)

Record details

Record id
cardio:ct-nct01132768
Content hash
967e65d9bcdff5493f2b5ca646ba0f60b7592234b02eeb4b44883ea81cb03289